Outpost Bio
Category: AI in Biotech / Drug Discovery
Building the AI layer for human microbiology — decoding the microbiome with a lab-in-the-loop platform that combines automated wet-lab experiments with causal machine learning models. Outpost Bio was founded in 2025. The company is led by Jenny Yang, PhD. Based in London, UK & Boston, USA. Team size: 1-10. Total funding raised: $3.5M. Latest round: Pre-Seed. Key investors include Merantix Capital, Seedcamp, OpenSeed VC, Defined Capital, Strategic family offices and angel investors.
- Founded
- 2025
- Headquarters
- London, UK & Boston, USA
- Team size
- 1-10
- Total funding
- $3.5M
Value proposition
Outpost Bio makes human microbiology computable by pairing high-throughput biological assays with causal AI to predict how drugs, ingredients, and formulations interact with the human microbiome — enabling pharma, food, and consumer health companies to de-risk R&D, flag safety issues earlier, and make sharper go/no-go decisions.
Products and solutions
Lab-in-the-Loop Platform (combines high-throughput experiments with ML in a continuous cycle), Frontier AI models trained on proprietary human-derived microbial community data, Open-source models (Waypoint — first open-source model with 500K+ data points), In vitro gut microbiome models ("gut in a tube"), Multi-omics capture (genomic + metabolomic readouts), Drug R&D de-risking (metabolism, toxicity, efficacy screening), Ingredient R&D de-risking (community shifts, metabolic output, safety screening)
Unique value
Causal (not merely correlative) AI models of the human microbiome built on proprietary human-derived data; Lab-in-the-Loop approach where experiments and ML continuously refine each other; Open-source ethos (Apache 2.0) with scientific reproducibility and peer-reviewed validation; Focus on human-derived samples (not mouse data) for translational relevance
Target customer
Pharmaceutical R&D teams (drug metabolism, toxicity, efficacy screening); Food & consumer product companies (ingredient safety, prebiotic/probiotic testing); CPG companies developing health formulations
Industries served
Pharmaceuticals, Food & Nutrition, Consumer Health / CPG, Biotechnology
Technology advantage
Lab-in-the-Loop platform combining automated wet-lab experimentation with causal ML; Proprietary human-derived microbial community biobank (geographically diverse stool samples); Causal AI models that identify mechanisms (not just correlations); Open-source strategy lowers adoption barriers for pharma/CPG partners; Multi-omics data generation (genomics + metabolomics) at scale; Team combines deep microbiology, ML, and operational experience from Amazon/AWS, Oxford, Ginkgo Bioworks
How they differentiate
Unlike traditional microbiome therapeutics companies (Vedanta, Seres) that develop live biotherapeutic products, Outpost Bio is an AI-first platform company building predictive models of microbial interactions — not therapeutics. Unlike bioinformatics-only approaches, Outpost combines its own wet-lab experimental data generation with ML in a closed loop. Its open-source strategy (Apache 2.0) and focus on causal (not correlative) models differentiates it from most competitors who keep data proprietary. The company targets pharma/CPG R&D de-risking rather than direct therapeutic development.
Main competitors
Vedanta Biosciences, Seres Therapeutics, BiomX, Kaleido Biosciences, Day Two, AFYREN, Spore Biotechnologies
Key partnerships
Academic partners and CROs for data generation and validation, Advisors: Anna Marie Wagner (former Head of AI, Ginkgo Bioworks), Dr. Steven Jones (Scientific Director, Genome Sciences Centre), Dr. Brad Ringeisen (former Director, DARPA Biological Technologies Office), Pledge 1% member (donates 1% profit, 1% employee time, 1% founder equity, 1% product to charity)
Major milestones
Founded 2025 by Jenny Yang (Oxford PhD, Marie Curie Fellow) and Alex Merwin (ex-Amazon/AWS Health & Bio), Raised $3.5M pre-seed (March 2026), Released first open-source model (Waypoint) with 500K+ data points, Validated in vitro gut microbiome models with external research organizations, Incorporated in UK (Companies House #16594666, July 2025)
Market positioning
Early-stage deep-tech startup positioning as the AI infrastructure layer for human microbiology — targeting pharma, food, and consumer health R&D teams that need predictive models of microbiome interactions to de-risk product development. Competes at the intersection of AI-driven drug discovery and microbiome science.
Geographic focus
Global (London, UK and Boston, US operations); Targeting pharma and CPG companies primarily in US and Europe
About Jenny Yang, PhD
Oxford PhD & Marie Curie Fellow; AI in cancer genomics & drug discovery; expertise in clinical ML & bioinformatics; previously at University of Oxford (DPhil candidate), KU Leuven, Siemens Digital Industries Software, Exscientia
Latest news about Outpost Bio
More AI in Biotech / Drug Discovery companies
Official website: https://www.outpost.bio